



Retrospective Study

# Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer

Ying-Jie Li, Dong-Xin Tang, Hong-Ting Yan, Bing Yang, Zhu Yang, Feng-Xi Long

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Batra SK, United States; Chiang SF, Taiwan

**Received:** April 24, 2023

**Peer-review started:** April 24, 2023

**First decision:** May 8, 2023

**Revised:** May 27, 2023

**Accepted:** June 13, 2023

**Article in press:** June 13, 2023

**Published online:** July 6, 2023



**Ying-Jie Li**, Guizhou University of Traditional Chinese Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang 550005, Guizhou Province, China

**Dong-Xin Tang, Bing Yang**, Digestive Department, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, Guizhou Province, China

**Hong-Ting Yan, Zhu Yang**, Guizhou University of Traditional Chinese Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang 550001, Guizhou Province, China

**Feng-Xi Long**, Guizhou University of Traditional Chinese Medicine, Guizhou University of Traditional Chinese Medicine, Gui Yang 550001, Guizhou Province, China

**Corresponding author:** Dong-Xin Tang, MD, Doctor, Digestive Department, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, No. 71 Baoshan North Road, Nanming District, Guiyang 550001, Guizhou Province, China.

[tangdongxin@sina.com](mailto:tangdongxin@sina.com)

## Abstract

### BACKGROUND

To analyze the potential action mechanism of Huangqin decoction (HQD) in colorectal cancer (CRC) treatment on the basis of network pharmacology and molecular docking.

### AIM

To investigate the molecular mechanisms of HQD for CRC treatment by using network pharmacology and molecular docking.

### METHODS

All HQD active ingredients were searched using the Systematic Pharmacology and Traditional Chinese Medicine Systems Pharmacology databases and the Bioinformatics Analysis Tool for Molecular Mechanisms in traditional Chinese medicine. Then, the targets of the active ingredients were screened. The abbreviations of protein targets were obtained from the UniProt database. A "drug-compound-target" network was constructed to screen for some main active ingredients. Some targets related to the therapeutic effect of CRC were obtained from the GeneCards, DisGeNET, Therapeutic Target Database, and Online

Mendelian Inheritance in Man databases. The intersection of targets of Chinese herbs and CRC was taken. A Venn diagram was drawn to construct the intersection target interactions network by referring to the STRING database. Topological analysis of the protein interaction network was performed using Cytoscape 3.7.2 software to screen the core HQD targets for CRC. The core targets were imported into the DAVID 6.8 analysis website for gene ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses and visualization. Finally, molecular docking was performed using AutoDockTool and PyMOL for validation.

## RESULTS

In total, 280 potential drug-active ingredients were present in HQD, including 1474 targets of the drug-active ingredients. The main active ingredients identified were betulin, tetrahydropalmatine, and quercetin. In total, 10249 CRC-related targets and 1014 drug-disease intersecting targets were identified, including 28 core targets of action such as Jun proto-oncogene, AP-1 transcription factor subunit, signal transducer and activator of transcription 3, tumor protein p53, vascular endothelial growth factor, and AKT serine/threonine kinase 1. The gene ontology enrichment functional analysis yielded 503 enrichment results, including 406 biological processes that were mainly related to the positive regulation of both gene expression and transcription and cellular response to hypoxia, *etc.* In total, 38 cellular components were primarily related to polymer complexes, transcription factor complexes, and platelet alpha granule lumen. Then, 59 molecular functions were closely related to the binding of enzymes, homologous proteins, and transcription factors. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis yielded 139 enrichment results, involving epidermal growth factor receptor tyrosine kinase inhibitor resistance and HIF-1 and mitogen-activated protein kinase signaling pathways.

## CONCLUSION

HQD can play a role in CRC treatment through the “multi-component-target-pathway”. The active ingredients betulin, tetrahydropalmatine, and quercetin may act on targets such as Jun proto-oncogene, AP-1 transcription factor subunit, signal transducer and activator of transcription 3, tumor protein p53, vascular endothelial growth factor, and AKT serine/threonine kinase 1, which in turn regulate HIF-1 and mitogen-activated protein kinase signaling pathways in CRC treatment. The molecular docking junction clarified that all four key target proteins could bind strongly to the main HQD active ingredients. This indicates that HQD could slow down CRC progression by modulating multiple targets and signaling pathways.

**Key Words:** Huangqin decoction; Colorectal cancer; Network pharmacology

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Huangqin decoction may treat colorectal cancer through multi-component targeting and modulation of multiple signaling pathways.

**Citation:** Li YJ, Tang DX, Yan HT, Yang B, Yang Z, Long FX. Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer. *World J Clin Cases* 2023; 11(19): 4553-4566

**URL:** <https://www.wjgnet.com/2307-8960/full/v11/i19/4553.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v11.i19.4553>

## INTRODUCTION

The incidence of colorectal cancer (CRC) has continued to increase, accounting for nearly 10% of cancer patients. CRC is the second most common cause of cancer death[1,2]. Many pathogenic factors could cause CRC such as obesity, poor diet, alcohol addiction, and genetic mutations or familial inheritance[1-4]. According to domestic statistics, CRC incidence in China has increased each year from 1990 to 2019. Using the ARIMA model, the standardized CRC incidence in China is predicted to reach 33.93/100000 in 2025, bringing a huge burden to the Chinese healthcare system[5]. Radical surgical resection, chemotherapy, radiotherapy, and targeted therapy are the current main treatment modalities for CRC [6]. However, these treatments are generally deficient as they are prone to recurrence and side effects. Therefore, finding effective drugs with few side effects in CRC treatment is valuable.

CRC is classified as “viscera toxin” and “intestinal accumulation” in traditional Chinese medicine (TCM). In the early CRC stage, clearing heat, regulating qi, dispelling dampness, eliminating phlegm, removing blood stasis, detoxifying, soft, and firm dispersing, and other treatment methods are used in TCM for dispelling evil spirits[7]. Huangqin Decoction (HQD) is derived from “Treatise on Febrile Diseases: Taiyang and Shaoyang combined disease, diarrhea, treat with HQD.” The HQD recipe consists of *Scutellariae Radix* (3 taels), *Paeonia lactiflora* Pall. (2 taels), *Glycyrrhiza uralensis* Fisch. (2 taels), and *Ziziphus jujuba* Mill. (12 pieces). *Scutellariae Radix* for the king, bitter, and cold can clear heat. *Paeonia lactiflora* Pall. can relieve pain. HQD can supply the qi. The combination of various drugs can clear heat and relieve pain[8]. HQD has been proven to treat CRC clinically with a remarkable effect, but the exact mechanism has not been elucidated.

TCM is based on the formulation principles of “king, minister, adjuvant, and ambassador” and incompatibility taboo. With the characteristics of the multi-component-target-pathway and synergistic treatment, TCM has great potential to improve cancer symptoms. Network pharmacology is an emerging discipline based on systems biology theories. It analyses and calculates the relationship between relevant drugs and diseases through drug-compound-target interaction networks[9]. By inferring the treatment effects and regulatory mechanisms of drugs in disease through multiple targets, it also provides new methods for TCM application, thereby facilitating the promotion of the development and heritage of Chinese herbs and compounds. Using informatics, molecular docking predicts the potential binding conformation of ligands and receptors. It also verifies the binding affinity of core components and targets. We here constructed a drug-compound-target network according to the HQD active ingredients by using network pharmacology and molecular docking and thus analyzed and calculated the molecular mechanism and regulation signal pathways of HQD for CRC treatment. The study findings also provided a certain theoretical basis for future studies.

## MATERIALS AND METHODS

### **Screening of bioactive components and targets of HQD**

In this study, Traditional Chinese Medicine Systems Pharmacology and Bioinformatics Analysis Tool for Molecular Mechanisms in traditional Chinese medicine databases were used to search the constituent herbs of HQD and their chemical and pharmacological data. Duplicate compounds were combined and removed to gather information about the HQD active ingredients. The targets of all these active ingredients were further searched and screened by referring to Traditional Chinese Medicine Systems Pharmacology and UniProt to realize the herb targets of HQD. All database URLs in this study are shown in Table 1.

### **Construction of drug-compound-target interaction networks**

We analyzed the obtained components and targets and constructed a network of “drug-compound-target” by using Cytoscape 3.7.2. In this network, nodes represent drugs, compounds, and targets, and edges represent the relationship between the three nodes. We analyzed the number of connections of each node by calculating the “degree” value.

### **Screening for CRC-related targets**

The term “colorectal cancer” was searched, and potential targets were screened for in GeneCards, TTD, OMIM, and DisGeNET databases. All CRC-related targets were acquired after removing duplicate targets. HQD action targets and CRC-related targets were imported into the online Wayne tool to map the intersection of HQD and CRC targets and visualize the results.

### **Construction of the protein-protein interaction network and screening for core targets**

To elucidate the functional interactions between the screened proteins, the intersecting targets were put into the STRING database to construct the protein-protein interaction (PPI) network. This PPI network was then put into Cytoscape 3.7.2, and the CytoNCA plugin was applied to filter core proteins based on betweenness (BC), closeness (CNC), degree (DC), eigenvector (EC), local average connectivity (LAC)-based method, and network (NC) 2 times the median value of the core proteins.

### **Gene ontology function and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses**

We obtained information about the primary biological processes and signaling pathways by importing the screened core targets into the DAVID 6.8 database for gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Then, the enrichment results were visualized using the LianChuan BioCloud platform.

### **Molecular docking of active ingredients to core targets**

The three-dimensional (3D) structure of the core target proteins was first obtained from the PDB database. The MOL2 file of the core active compounds was then obtained from the PubChem platform. Chem 3D was used to optimize the total amount of core component energy. PyMOL software was used to optimize the number of core target proteins removed for water molecule hydrogenation and charge calculation. Molecular docking and binding activity analyses were performed using the AutoDock Vina program. Finally, docking sites were visualized on the PLIP platform. When the binding energy of the molecular docking conformation was lower, the binding conformation was more stable. This reflects the greater likelihood of binding between the receptor molecule and ligand. Therefore, only the highest absolute value of binding energy for each molecular docking pair was retained for the docking results.

## **RESULTS**

We identified the HQD active ingredients and the potential therapeutic targets and mechanisms of HQD in CRC treatment by conducting network pharmacology and functional gene pathway analyses.

### **Screening of bioactive ingredients and targets of HQD**

Among the active ingredients obtained, 46 were *Scutellariae Radix*, 28 were *Paeonia lactiflora* Pall., 160 were *Glycyrrhiza uralensis* Fisch., and 58 were *Ziziphus jujuba* Mill. Then, 280 compounds and 1474 potential targets were obtained for the action of the ingredients after removing the duplicate information.

### **Construction of drug-compound-target network**

The network “drug-compound-target” was built using Cytoscape 3.7.1 software. It included 1695 nodes and 5567 edges (Figure 1), with red squares representing drug co-components. The specific information is presented in Table 2. The HQD compounds with high activity are betulin, tetrahydropalmatine, and quercetin, which may be crucial for CRC treatment.

### **Screening for CRC-related targets**

We obtained 10249 CRC-related targets for its treatment from the disease databases of Genecards, OMIM, DisGeNET, and TTD. The targets of both CRC and the HQD active ingredients were imported into the Venn diagram editing website, and then 1014 potential targets of HQD in CRC treatment were identified (Figure 2).

### **PPI network analysis and key target screening**


The STRING was used to obtain key proteins for CRC treatment with HQD. The analysis data were imported into Cytoscape 3.7.2. Based on the BC, CNC, DC, EC, LAC, and NC values of topological parameters calculated using CytoNCA, 28 targets that play key roles in CRC, such as Jun proto-oncogene, AP-1 transcription factor subunit (JUN), signal transducer and activator of transcription 3 (STAT3), tumor protein p53 (TP53), vascular endothelial growth factor (VEGFA), and AKT serine/threonine kinase 1 (AKT1) were screened (Figure 3). These targets could be considered the HQD core targets in CRC treatment.

### **GO function and KEGG pathway enrichment analyses**

We imported 28 core targets into the DAVID 6.8 database to identify the relevant HQD biological functions in CRC treatment by analyzing GO functional enrichment. This analysis revealed 503 enrichment results, including 406 biological processes, 38 cellular components, and 59 molecular functions. The biological processes were mainly related to the positive regulation of gene expression and transcription and cellular response to hypoxia. The cellular components were principally related to the macromolecular complex, transcription factor complex, platelet alpha granule lumen, *etc.* The molecular functions primarily involved the binding of enzymes, identical proteins, and transcription factors. The GO enrichment results were sorted from the smallest to the largest *P* value. The top 10 entries were selected to create a histogram (Figure 4). To determine the potential mechanism underlying CRC treatment with HQD, we performed the KEGG pathway enrichment analysis and obtained 139 HQD-associated signaling pathways for CRC treatment. The top 20 pathways were visualized in descending order of the *P* value (Figure 5). These mainly included signaling pathways such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance, HIF-1, and mitogen-activated protein kinase (MAPK), suggesting that HQD can treat CRC through these pathways.

### **Molecular docking of potential active ingredients to core target proteins**

Five key target proteins (JUN, STAT3, TP53, VEGFA, and AKT1) were molecularly docked to three core components (betulin, tetrahydropalmatine, and quercetin) to assess the binding capacity of the target and ligand proteins. The binding capacity was predicted using AutoDock software, with binding




**Figure 1 Drug-compound-target network.** The yellow ovals represent the potential genes. The pink circles represent the active ingredients of glycyrrhiza. The light blue circles represent the active ingredients of Paeonia lactiflora Pall. The dark blue circles represent the active ingredients of Scutellariae Radix. The green circles represent the active ingredients of Ziziphus jujuba Mill. The red squares represent the active ingredients of all herbs.

energies typically  $< -5.0$  kcal mol<sup>-1</sup> indicating significant binding activity between the molecules. All three active components exhibited a strong binding capacity to JUN, TP53, VEGFA, and AKT1 (Table 3), with birudinol failing to bind well to STAT3. The 3D model plots of the three active ingredients docked with JUN, TP53, VEGFA, and AKT1 were visualized using PyMOL and PLIP software (Figures 6-8).

Table 1 The web addresses of databases	
Database	Address
TCMSP	<a href="http://www.tcmspw.com/tcmsp.php">http://www.tcmspw.com/tcmsp.php</a>
BATMAN-TCM	<a href="http://bionet.ncpsb.org.cn/batman-tcm/">http://bionet.ncpsb.org.cn/batman-tcm/</a>
Genecards	<a href="https://www.genecards.org">https://www.genecards.org</a>
TTD	<a href="http://bidd.nus.edu.sg/group/ttd/ttd.asp">http://bidd.nus.edu.sg/group/ttd/ttd.asp</a>
OMIM	<a href="https://omim.org/">https://omim.org/</a>
DisGeNET	<a href="https://www.disgenet.org/home/">https://www.disgenet.org/home/</a>
Wayne tool	<a href="http://jvenn.toulouse.inra.fr/app/example.html">http://jvenn.toulouse.inra.fr/app/example.html</a>
String	<a href="https://string-db.org/">https://string-db.org/</a>
DAVID 6.8	<a href="http://david.ncifcrf.gov">http://david.ncifcrf.gov</a>
Omicstudio	<a href="https://www.omicstudio.cn/tool">https://www.omicstudio.cn/tool</a>
PDB	<a href="https://www.rcsb.org">https://www.rcsb.org</a>
PubChem	<a href="https://pubchem.ncbi.nlm.nih.gov">https://pubchem.ncbi.nlm.nih.gov</a>


TCMSP: Traditional Chinese Medicine Systems Pharmacology; TTD: Therapeutic target Database; OMIM: Online Mendelian Inheritance in Man; BATMAN-TCM: Bioinformatics Analysis Tool for Molecular Mechanisms in traditional Chinese medicine.



**Figure 2 Huangqin decoction–colorectal cancer intersection target.** A: Targets of Huangqin decoction; B: Colorectal cancer-related targets. CRC: Colorectal cancer; HQD: Huangqin decoction.


DISCUSSION

According to TCM, the diseased region in CRC is the large intestine. Moreover, CRC is closely related to the spleen and stomach. “Miraculous Pivot” mentioned that “The injury of the stomach, the blood overflow in the parenteral, the parenteral cold, the juice foam and blood phase kneading, the combination of condensation cannot be dispersed, and the product into.” Several clinical studies have retrospectively investigated the TCM symptoms of CRC patients and their associated factors. These studies have found that the most common TCM classification of CRC is the syndrome of damp heat accumulation[10-12]. HQD was first mentioned by Zhang Zhongjing in “Treatise on Febrile Diseases.” According to this monograph, HQD could clear away heat and relieve pain and is a classic therapeutic formula for damp heat in Chinese medicine.




**Figure 3 The core target screening process.** A: All potential targets of Huangqin decoction in the treatment of colorectal cancer (purple nodes); B: Core targets screened based on CytoNCA (yellow nodes); C: The top 28 targets screened by betweenness, closeness, degree, eigenvector, local average connectivity and network values of topology parameters. JUN: Jun proto-oncogene, AP-1 transcription factor subunit; STAT3: Signal transducer and activator of transcription 3; TP53: Tumor protein p53; VEGFA: Vascular endothelial growth factor; AKT1: AKT serine/threonine kinase 1 (AKT1); MAPK: Mitogen-activated protein kinase; EGFR: Epidermal growth factor receptor.

We conducted a network pharmacological analysis to determine active compounds, potential targets, and action mechanisms of HQD in CRC treatment. In total, 280 core ingredients of HQD were screened. The topological analysis of the “drug-compound-target” network revealed that the top-ranked compounds were betulin, tetrahydropalmatine, and quercetin. These may be the potential compounds of HQD in CRC treatment. Among them, betulinol induced apoptosis of CRC cells through the MAPK signaling pathway and significantly inhibited malignant metastasis of CT26 cells in the lungs[13]. The




**Figure 4 Gene ontology functional enrichment analysis.** The purple bars represent biological processes, the blue bars represent cellular components, and the green bars represent molecular functions. GO: Gene ontology.



**Figure 5 Kyoto Encyclopedia of genes and genomes pathway enrichment analysis.** The top 20 signaling pathways of Huangqin decoction are involved in the treatment of colorectal cancer. The size of nodes is proportional to the number of genes enriched. KEGG: Kyoto Encyclopedia of Genes and Genomes; EGFR: Epidermal growth factor receptor; MAPK: EGFR: Mitogen-activated protein kinase.

therapeutic efficacy of tetrahydropalmatine has been demonstrated in various cancers[14,15], suggesting that tetrahydropalmatine can be used as a potential novel therapeutic agent for CRC patients. Quercetin, a flavanol compound, has various biological activities, such as antioxidant activity. Quercetin could interfere with CRC development in various ways, such as inhibiting growth and proliferation and affecting the cycle of CRC cells. Thus, it could induce apoptosis and inhibit metastasis and invasion of



**Figure 6** The docking model of the core active ingredient betulinol with the target proteins. A: Docking of betulinol to Jun proto-oncogene, AP-1 transcription factor subunit; B: Docking of betulinol to vascular endothelial growth factor; C: Docking of betulinol to tumor protein p53; D: Docking of betulinol to AKT1 serine/threonine kinase 1. JUN: Jun proto-oncogene, AP-1 transcription factor subunit; VEGFA: Vascular endothelial growth factor; TP53: Tumor protein p53; AKT1: AKT serine/threonine kinase 1.

CRC[16-19]. The aforementioned results proved that the main active ingredients of HQD play a crucial role in CRC treatment, suggesting that HQD is an effective therapeutic formula for CRC treatment.

On the basis of BC, CNC, DC, EC, LAC, and NC, the top five key targets, namely JUN, STAT3, TP53, VEGFA, and AKT1, were finally screened through cascading analysis of key targets using the PPI network. JUN is a transcription factor that recognizes and binds to the enhanced heptameric motif 5'-TGA[CG]TCA-3'. JUN can upregulate HuR expression by inhibiting miR-22 transcriptional regulation, which in turn leads to proliferation, migration, and tumor growth in CRC cells[20].

STAT3, a member of the STAT cytoplasmic transcription factor family, is the family member most associated with CRC development[21]. Large amounts of STAT3 are activated in CRC to promote tumor growth, invasion, migration[22], and proliferation of cancer cells. These features suggest that STAT3 can be used as a therapeutic target in CRC.


TP53 encodes the tumor suppressor p53, which is the major driver gene for suppressing the development of various cancers. The TP53 mutation has been observed in up to 80% of patients with advanced metastatic CRC[23], and this mutation can lead to poor prognosis in various cancer patients, including CRC patients[24].

VEGFA, the subtype of the vascular endothelial growth factor (VEGF), has a critical role in angiogenesis. According to some studies, tumor growth, spread, and metastasis depend on angiogenesis. VEGFA is a major proangiogenic factor in CRC and is strongly related to metastasis in this cancer[25]. The receptor targeting the tyrosine kinase VEGF can inhibit the angiogenesis, proliferation, and growth of liver metastases in CRC. This anti-angiogenic therapy significantly increases endothelial and tumor cell apoptosis, thereby suggesting that VEGF has a crucial role in the tumor endothelium[26].

AKT is a member of the serine/threonine kinase proto-oncogene family that regulates different inflammatory and metabolism-related signaling pathways and is involved in cancer cell proliferation,

Table 2 Common active ingredients information for Huangqin decoction				
Numbers	Mol ID	Molecule name	OB (%)	DL
A1	MOL000359	Sitosterol	36.91	0.75
A2	MOL000211	Mairin	55.38	0.78
A3	MOL000422	Kaempferol	41.88	0.24
A4	MOL008583	Beta-sitosterol	15.00	0.81
A5	MOL000492	(+)-Catechin	54.83	0.24
A6	MOL000096	(-)-Catechin	49.68	0.24
B1	MOL002320	γ-Sitosterol	36.91	0.75
B2	MOL002307	20-Hexadecanoylingenol	28.20	0.68
C1	MOL004349	Ruvoside	18.13	0.63
C2	MOL000098	Quercetin	46.43	0.28

OB: Oral bioavailability; DL: Drug- likeness.




**Figure 7** The docking model of the key active ingredient tetrahydropalmatine to the target proteins. A: Docking of tetrahydropalmatine to Jun proto-oncogene, AP-1 transcription factor subunit; B: Docking of tetrahydropalmatine to tumor protein p53; C: Docking of tetrahydropalmatine to vascular endothelial growth factor; D: Docking of tetrahydropalmatine to AKT1 serine/threonine kinase 1. JUN: Jun proto-oncogene, AP-1 transcription factor subunit; TP53: Tumor protein p53; VEGFA: Vascular endothelial growth factor; AKT1: AKT serine/threonine kinase 1.

**Table 3 Molecular docking results**

Active ingredients	Binding energy (kcal/mol)			
	JUN	TP53	VEGFA	AKT1
Betulinol	-8.4	-6	-8.7	-10.3
Tetraydropalmatine	-7.2	-6.1	-9.4	-9.6
Quercetin	-6.4	-8.3	-8.1	-8.3

JUN: Jun proto-oncogene, AP-1 transcription factor subunit; TP53: Tumor protein p53; VEGFA: Vascular endothelial growth factor; AKT1: AKT serine/threonine kinase 1.



**Figure 8** The docking model of the key active ingredient quercetin to the target proteins. A: Docking of quercetin to Jun proto-oncogene, AP-1 transcription factor subunit; B: Docking of quercetin to tumor protein p53; C: Docking of tetrahydropalmatine to vascular endothelial growth factor; D: Docking of tetrahydropalmatine to AKT1 serine/threonine kinase 1. JUN: Jun proto-oncogene, AP-1 transcription factor subunit; TP53: Tumor protein p53; VEGFA: Vascular endothelial growth factor; AKT1: AKT serine/threonine kinase 1.

survival, and metabolic processes[27]. Approximately 70% of CRC exhibits highly activated AKT, which is closely associated with cancer development.

During molecular docking, the three core ingredients of HQD exhibited strong affinity to the four key target proteins, confirming the targeting effect of HQD in CRC treatment. The predicted results thus theoretically elucidate the ameliorative effect of HQD on CRC and help in the further investigation of the action mechanism of HQD or its bioactive compounds as an alternative treatment for CRC. The GO functional enrichment suggested that CRC treatment with HQD was mainly related to the positive regulation of gene expression and transcription as well as a cellular response to hypoxia. The KEGG pathway revealed that the pathways most closely related to CRC were EGFR tyrosine kinase inhibitor

resistance, and HIF-1 and MAPK signaling pathways.

EGFR is closely associated with CRC recurrence and deterioration. Studies have demonstrated that miR-323a-3p can promote the apoptosis of CRC cells by directly targeting EGFR signaling[28]. Acquired resistance to 5-fluorouracil is a clinical challenge for CRC treatment. The HIF-1 $\alpha$  and 5-fluorouracil combination significantly enhances the antitumor effects of 5-fluorouracil[29]. Therefore, targeting HIF-1 $\alpha$  could act as an effective therapeutic strategy for 5-fluorouracil-resistant CRC. The MAPK signaling pathway is activated by peptide growth factors, cytokines, oxidative stress, *etc.* This pathway then regulates tumor cell proliferation, differentiation, survival, and death[30]. Several MAPK, ERK, c-Jun, and JNK subfamilies are involved in CRC pathogenesis[31], with ERK/MAPK playing a crucial role in cell proliferation[30]. Therefore, EGFR tyrosine kinase inhibitor resistance and HIF-1 and MAPK signaling pathways are closely linked to CRC development.

## CONCLUSION

In conclusion, by analyzing “multi-components-targets-biological pathways,” this study found that HQD could exert therapeutic effects. Our findings also provide a clue regarding the theoretical basis for the active ingredients of HQD that are most effective in CRC treatment. However, because of the deficiencies of network pharmacology and molecular docking, follow-up *in vivo* and *in vitro* experiments are warranted to verify the action mechanism of HQD in CRC treatment.

## ARTICLE HIGHLIGHTS

### Research background

Colorectal cancer (CRC) is the second most common cause of cancer death in recent years. CRC is a danger to human health.

### Research motivation

The side effects caused by radiotherapy severely hinder the treatment progress of CRC patients. Huangqin decoction (HQD) can improve the immunity of CRC patients and enhance their quality of life.

### Research objectives

This study exploited network pharmacology and molecular docking to uncover the potential targets and mechanisms of HQD for CRC treatment. It also provided a molecular biological basis for CRC treatment with HQD in a clinical setting.

### Research methods

This study involved preliminary exploration of the potential targets and mechanisms of HQD for CRC treatment by using network pharmacology and molecular docking.

### Research results

The active ingredients betulin, tetrahydropalmatine, and quercetin in HQD may act on targets such as Jun proto-oncogene, AP-1 transcription factor subunit, signal transducer and activator of transcription 3, tumor protein p53, vascular endothelial growth factor, and AKT serine/threonine kinase 1, which in turn regulate HIF-1 and mitogen-activated protein kinase signaling pathways in CRC treatment.

### Research conclusions

HQD could treat CRC by regulating HIF-1 and mitogen-activated protein kinase signaling pathways.

### Research perspectives

At present, many shortcomings still exist in studying the action mechanisms of herbal medicine for various diseases on the basis of network pharmacology. Future research should be focused on *in vivo* and *in vitro* experiments to verify the key targets and type pathways and then combined proteomics and metabolomics to more systematically elucidate the action mechanism of HQD in CRC treatment.

## FOOTNOTES

**Author contributions:** Li YJ and Tang DX contributed equally to this work; Yan HT designed the study; Yang B contributed to the analysis of the manuscript; Yang Z and Long FX were involved in the data acquisition and writing of this article; All authors read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 82260957; No. 82274610; No. 81860819; No. 81860819; and No. 81960818; Guizhou Provincial Science and Technology Program (Qian Kehe Foundation-ZK[2022] General 498, Qian Kehe Foundation-ZK [2022] General 487, Qian Kehe Support [2021] General 095, Qian Kehe Platform Talent [2020]5013); National Key R&D Program Project (2019YFC1712504); Guizhou Traditional Chinese Medicine Tumor Inheritance and Science and Technology Innovation Talent Base (No. Deaf leader-[2018] No. 3); Guizhou high-level innovative talent training plan (100 levels) (No. Qian Kehe Talents [2016] No. 4032); Yang Zhu, Guizhou Province, "Traditional Chinese Medicine Oncology" Graduate Tutor Studio (No. Teaching and research GZS-[2016]08).

**Institutional review board statement:** The study was reviewed and approved by the Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China, Institutional Review Board.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Ying-Jie Li 0009-0007-3447-6460; Dong-Xin Tang 0000-0002-6622-2744; Hong-Ting Yan 0009-0002-5204-8500; Bing Yang 0009-0007-9479-177X; Zhu Yang 0009-0004-9899-9250; Feng-Xi Long 0009-0009-2033-5653.

**S-Editor:** Ma YJ

**L-Editor:** Filipodia

**P-Editor:** Zhao S

## REFERENCES

- 1 Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. *CA Cancer J Clin* 2020; **70**: 145-164 [PMID: 32133645 DOI: 10.3322/caac.21601]
- 2 Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. *JAMA* 2021; **325**: 669-685 [PMID: 33591350 DOI: 10.1001/jama.2021.0106]
- 3 Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 713-732 [PMID: 31455888 DOI: 10.1038/s41575-019-0189-8]
- 4 de la Chapelle A, Peltomäki P. Genetics of hereditary colon cancer. *Annu Rev Genet* 1995; **29**: 329-348 [PMID: 8825478 DOI: 10.1146/annurev.ge.29.120195.001553]
- 5 Liu Y, Zhang C, Wang Q, Wu K, Sun Z, Tang Z, Zhang B. Temporal Trends in the Disease Burden of Colorectal Cancer with Its Risk Factors at the Global and National Level from 1990 to 2019, and Projections Until 2044. *Clin Epidemiol* 2023; **15**: 55-71 [PMID: 36659904 DOI: 10.2147/CLEP.S388323]
- 6 Zheng Y, Fu Y, Wang PP, Ding ZY. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer. *Dis Markers* 2022; **2022**: 8270305 [PMID: 35211210 DOI: 10.1155/2022/8270305]
- 7 Sun L, Mao JJ, Yan Y, Xu Y, Yang Y. Patient Reported Traditional Chinese Medicine Spleen Deficiency Syndrome (TCM-SDS) Scale for Colorectal Cancer: Development and Validation in China. *Integr Cancer Ther* 2021; **20**: 15347354211020105 [PMID: 34116615 DOI: 10.1177/15347354211020105]
- 8 Xu DD, Hou XY, Wang O, Wang D, Li DT, Qin SY, Lv B, Dai XM, Zhang ZJ, Wan JB, Xu FG. A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan. *Chin J Nat Med* 2021; **19**: 364-375 [PMID: 33941341 DOI: 10.1016/S1875-5364(21)60034-1]
- 9 Pei T, Zheng C, Huang C, Chen X, Guo Z, Fu Y, Liu J, Wang Y. Systematic understanding the mechanisms of vitiligo pathogenesis and its treatment by Qubaibabuqi formula. *J Ethnopharmacol* 2016; **190**: 272-287 [PMID: 27265513 DOI: 10.1016/j.jep.2016.06.001]
- 10 Wang YN, Zou M, Wang D, Zhang ZK, Qu LP, Xu J, Shi CD, Gao F. An exploratory study on TCM syndrome differentiation in preoperative patients with colorectal cancer assisted by laboratory indicators. *Heliyon* 2022; **8**: e10207 [PMID: 36033259 DOI: 10.1016/j.heliyon.2022.e10207]
- 11 Lu Y, Zhou C, Zhu M, Fu Z, Shi Y, Li M, Wang W, Zhu S, Jiang B, Luo Y, Su S. Traditional chinese medicine syndromes classification associates with tumor cell and microenvironment heterogeneity in colorectal cancer: a single cell RNA sequencing analysis. *Chin Med* 2021; **16**: 133 [PMID: 34876190 DOI: 10.1186/s13020-021-00547-7]
- 12 Wang P, Ding S, Sun L, Feng Y, Guo K, Zhu Y, Huang D, Ruan S. Characteristics and differences of gut microbiota in patients with different Traditional Chinese Medicine Syndromes of Colorectal Cancer and normal population. *J Cancer* 2020; **11**: 7357-7367 [PMID: 33193900 DOI: 10.7150/jca.50318]
- 13 Han YH, Mun JG, Jeon HD, Kee JY, Hong SH. Betulin Inhibits Lung Metastasis by Inducing Cell Cycle Arrest,

- Autophagy, and Apoptosis of Metastatic Colorectal Cancer Cells. *Nutrients* 2019; **12** [PMID: 31887988 DOI: 10.3390/nu12010066]
- 14 **Xia X**, He J, Liu B, Shao Z, Xu Q, Hu T, Yu C, Liu X, Liao Y, Liu N, Huang H. Targeting ER $\alpha$  degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. *Int J Biol Sci* 2020; **16**: 2192-2204 [PMID: 32549765 DOI: 10.7150/ijbs.44005]
- 15 **Gong J**, Xing C, Wang LY, Xie SS, Xiong WD. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin *via* microRNA-93/PTEN/Akt cascade. *J BUON* 2019; **24**: 701-708 [PMID: 31128026]
- 16 **Yang L**, Liu Y, Wang M, Qian Y, Dong X, Gu H, Wang H, Guo S, Hisamitsu T. Quercetin-induced apoptosis of HT-29 colon cancer cells *via* inhibition of the Akt-CSN6-Myc signaling axis. *Mol Med Rep* 2016; **14**: 4559-4566 [PMID: 27748879 DOI: 10.3892/mmr.2016.5818]
- 17 **Al-Ghamdi MA**, Al-Enazy A, Huwait EA, Albukhari A, Harakeh S, Moselhy SS. Enhancement of Annexin V in response to combination of epigallocatechin gallate and quercetin as a potent arrest the cell cycle of colorectal cancer. *Braz J Biol* 2021; **83**: e248746 [PMID: 34495165 DOI: 10.1590/1519-6984.248746]
- 18 **Raja SB**, Rajendiran V, Kasinathan NK, P A, Venkatabalasubramanian S, Murali MR, Devaraj H, Devaraj SN. Differential cytotoxic activity of Quercetin on colonic cancer cells depends on ROS generation through COX-2 expression. *Food Chem Toxicol* 2017; **106**: 92-106 [PMID: 28479391 DOI: 10.1016/j.fct.2017.05.006]
- 19 **Han M**, Song Y, Zhang X. Quercetin Suppresses the Migration and Invasion in Human Colon Cancer Caco-2 Cells Through Regulating Toll-like Receptor 4/Nuclear Factor-kappa B Pathway. *Pharmacogn Mag* 2016; **12**: S237-S244 [PMID: 27279714 DOI: 10.4103/0973-1296.182154]
- 20 **Liu Y**, Chen X, Cheng R, Yang F, Yu M, Wang C, Cui S, Hong Y, Liang H, Liu M, Zhao C, Ding M, Sun W, Liu Z, Sun F, Zhang C, Zhou Z, Jiang X. The Jun/miR-22/HuR regulatory axis contributes to tumorigenesis in colorectal cancer. *Mol Cancer* 2018; **17**: 11 [PMID: 29351796 DOI: 10.1186/s12943-017-0751-3]
- 21 **Corvinus FM**, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfizner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschlager P, Schütz A, Halbhauer KJ, Friedrich K. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. *Neoplasia* 2005; **7**: 545-555 [PMID: 16036105 DOI: 10.1593/neo.04571]
- 22 **Xiong H**, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, Fang JY. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. *Neoplasia* 2008; **10**: 287-297 [PMID: 18320073 DOI: 10.1593/neo.07971]
- 23 **Brannon AR**, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oswald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. *Genome Biol* 2014; **15**: 454 [PMID: 25164765 DOI: 10.1186/s13059-014-0454-7]
- 24 **Olivier M**, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol* 2010; **2**: a001008 [PMID: 20182602 DOI: 10.1101/cshperspect.a001008]
- 25 **Peeters M**, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice. *Cancer Treat Rev* 2012; **38**: 397-406 [PMID: 21899955 DOI: 10.1016/j.ctrv.2011.08.002]
- 26 **Ellis LM**, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. *Oncologist* 2000; **5** Suppl 1: 11-15 [PMID: 10804085 DOI: 10.1634/theoncologist.5-suppl\_1-11]
- 27 **Li D**, Wang G, Jin G, Yao K, Zhao Z, Bie L, Guo Y, Li N, Deng W, Chen X, Chen B, Liu Y, Luo S, Guo Z. Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway. *Int J Mol Med* 2019; **43**: 630-640 [PMID: 30387805 DOI: 10.3892/ijmm.2018.3969]
- 28 **Zhang Y**, Liang S, Xiao B, Hu J, Pang Y, Liu Y, Yang J, Ao J, Wei L, Luo X. MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer. *Cell Death Dis* 2022; **13**: 256 [PMID: 35319011 DOI: 10.1038/s41419-022-04709-9]
- 29 **Dong S**, Liang S, Cheng Z, Zhang X, Luo L, Li L, Zhang W, Li S, Xu Q, Zhong M, Zhu J, Zhang G, Hu S. ROS/PI3K/Akt and Wnt/ $\beta$ -catenin signalings activate HIF-1 $\alpha$ -induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. *J Exp Clin Cancer Res* 2022; **41**: 15 [PMID: 34998404 DOI: 10.1186/s13046-021-02229-6]
- 30 **Kim EK**, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. *Biochim Biophys Acta* 2010; **1802**: 396-405 [PMID: 20079433 DOI: 10.1016/j.bbdis.2009.12.009]
- 31 **Fang JY**, Richardson BC. The MAPK signalling pathways and colorectal cancer. *Lancet Oncol* 2005; **6**: 322-327 [PMID: 15863380 DOI: 10.1016/s1470-2045(05)70168-6]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

